Xuzhou Central Hospital
Xuzhou Central Hospital
Xuzhou, Jiangsu, China20 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | Airway Obstruction, Dyspnea, Hypersensitivity, Immediate, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Respiratory Hypersensitivity, Respiratory Sounds, Signs and Symptoms, Signs and Symptoms, Respiratory, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory failure, respiratory system disorder | Recruiting | Phase 2 | 2026-10-05 | NCT06977581 | |
| Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 3 | 2026-09-28 | NCT07464587 | |
| Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer | Platinum-sensitive Recurrent Ovarian Cancer | Not yet recruiting | Phase 3 | 2026-09-16 | NCT07821606 | |
| Pediatric Spinal Muscular Atrophy (SMA) China Registry | central nervous system disorder, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, spinal cord disorder, spinal muscular atrophy | Active, not recruiting | Not stated | 2026-09-11 | NCT05042921 | |
| Phase II Trial of RC1416 Injection in Asthma | Moderate to Severe Asthma | Recruiting | Phase 2 | 2026-09-10 | NCT07403487 | |
| Phase II Study of RC1416 Injection in COPD | Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Recruiting | Phase 2 | 2026-09-08 | NCT07402551 | |
| A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | HER2-positive Breast Cancer | Active, not recruiting | Phase 3 | 2026-07-23 | NCT03975647 | |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-07-22 | NCT05253651 | |
| A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer | HER2-positive Breast Cancer | Recruiting | Phase 3 | 2026-06-29 | NCT07673029 | |
| TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer | HER2-positive Advanced Breast Cancer | Recruiting | Phase 3 | 2026-06-03 | NCT07047365 | |
| Pulsed-Field Ablation With/Without Electrogram Mapping | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder | Active, not recruiting | Not applicable | 2026-04-21 | NCT07541989 | |
| Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China | Bone Diseases, Metabolic, Nutritional and Metabolic Diseases, bone disorder, metabolic disease, musculoskeletal system disorder, osteoporosis | Active, not recruiting | Phase 4 | 2026-02-12 | NCT06332014 | |
| Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Active, not recruiting | Phase 3 | 2025-12-17 | NCT06211036 | |
| A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Phase 3 | 2025-11-05 | NCT05837897 | |
| Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Not yet recruiting | Phase 3 | 2025-09-10 | NCT07147946 | |
| Optimal Ablation Strategies for Persistent AF With HF | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder, heart failure, persistent atrial fibrillation | Active, not recruiting | Not applicable | 2025-09-04 | NCT07153718 | |
| A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2025-06-10 | NCT05346224 | |
| D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2024-04-26 | NCT06300177 | |
| DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, gastroesophageal junction adenocarcinoma, neoplasm, stomach disorder | Recruiting | Phase 2 / Phase 3 | 2024-04-03 | NCT06221748 | |
| A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 2 | 2024-02-07 | NCT05678270 |